hsa-miR-182

ncRNA information

ncRNA name

hsa-miR-182

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

TP53INP1

Cancer information

Cancer name

Hepatocellular Carcinoma

Cancer site

Liver

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Up

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-182 increased cisplatin resistance of HCC cell, partly by targeting TP53INP1.

Tissue resource

blood samples

human embryonic kidney cell lines HEK-293T

hepatocellular carcinoma cell lines HepG2

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

Renji hospital affiliated to School of Medicine Shanghai Jiaotong University

American Type Culture Collection

Country

China

USA

Continent

Asia

Amercia